Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
17.7 BRL | +8.19% | +10.06% | +204.67% |
04-18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
04-17 | Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A | CI |
Sales 2022 | 105M 20.36M 1.63B | Sales 2023 | 118M 22.93M 1.83B | Capitalization | 470M 91.14M 7.29B |
---|---|---|---|---|---|
Net income 2022 | -92M -17.85M -1.43B | Net income 2023 | -81M -15.71M -1.26B | EV / Sales 2022 | 5.9 x |
Net Debt 2022 | 67.72M 13.14M 1.05B | Net Debt 2023 | 125M 24.23M 1.94B | EV / Sales 2023 | 5.03 x |
P/E ratio 2022 |
-5.37
x | P/E ratio 2023 |
-5.93
x | Employees | 130 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 47.6% |
1 day | +7.64% | ||
1 week | +10.06% | ||
Current month | +72.65% | ||
1 month | +77.70% | ||
3 months | +234.16% | ||
6 months | +266.88% | ||
Current year | +204.67% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | - | |
Director of Finance/CFO | - | 15/04/19 | |
Luciano Vilela
CTO | Chief Tech/Sci/R&D Officer | - | 19/02/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 31/01/14 | |
Director/Board Member | 84 | 12/10/15 | |
Director/Board Member | 81 | 15/12/13 |
Date | Price | Change | Volume |
---|---|---|---|
30/04/24 | 17.7 | +8.19% | 33 200 |
29/04/24 | 17.77 | +10.99% | 309,100 |
26/04/24 | 16.01 | +1.52% | 124,300 |
25/04/24 | 15.77 | -3.37% | 130,300 |
24/04/24 | 16.32 | +2.00% | 232,600 |
Delayed Quote Sao Paulo, April 30, 2024 at 02:54 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+204.67% | 310M | |
-3.09% | 102B | |
+1.05% | 96.29B | |
+1.78% | 22.18B | |
-15.78% | 21.2B | |
-9.58% | 18.31B | |
-38.74% | 17.38B | |
-13.48% | 16.36B | |
+6.57% | 13.97B | |
+33.68% | 12.17B |
- Stock Market
- Equities
- BIOM3 Stock